One of the key challenges of live cell implantation is the body's rejection of anything that "looks" foreign to the immune system. All too often a donated organ or tissue is attacked by the recipient immune system, causing a myriad of problems.
What if, however, those living cells could be encapsulated by a durable shell, allowing the cells inside to operate as usual, but protecting them from an attack by white blood cells?
That's exactly what Cell-in-a-Box from Pharmacyte Biotech Inc (OTCMKTS: PMCB ) does. That is, it envelopes a certain kind of cell in a strong but partially porous shell, allowing them to produce a variety of necessary enzymes, hormones, etc., but without inducing the tissue scarring that's been witnessed with other encapsulation attempts.
One capsule, about the size of the head of a pin, can hold thousands of cells.
To date, the Cell-in-a-Box platform has been used to activate cancer drugs very near the point of the tumor in pancreatic cancer patients , but the most exciting prospect of the biotechnology so far is the encapsulation of insulin-producing cells. That's right - Cell-in-a-Box may be a way of creating an artificial pancreas for diabetics .
Market Data 
Markets 
AI
